This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fullwood, P. Articles by Latif, F. Search for Related Content PubMed PubMed Citation Articles by Fullwood, P. Articles by Latif, F.

Detailed Genetic and Physical Mapping of Tumor Suppressor Loci on Chromosome 3p in Ovarian Cancer¹

Section of Medical and Molecular Genetics, Department of Pediatrics and Child Health, University of Birmingham, Birmingham B15 2TT, United Kingdom [P. F., A. M., D. M., E. R. M., F. L.]; Molecular Pharmacology Unit, Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri," 20157 Milan, Italy [S. M., M. B.]; Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri 63110 [J. S. R.]; and Institute of Microbiology and Interdepartment Center for Biotechnology, School of Medicine, University of Ferrara, I-44100 Ferrara, Italy [C. M., G. B-B.]

Hemizygosity and homozygosity mapping studies show that many common sporadic cancers including lung, breast, kidney, cervical, ovarian, and head and neck cancer display deletions on the short arm of chromosome 3. For ovarian cancer, monochromosomal transfer suppression studies have identified three candidate regions for chromosome 3p ovarian cancer tumor suppressor genes (OCTSGs). To accurately map OCTSG candidate regions, we analyzed 70 ovarian tumors for loss of heterozygosity (LOH) at 20 loci on chromosome 3p that were selected to target those regions proposed to contain tumor suppressor genes for common sporadic cancers. All samples were informative for at least five markers. In 33 (52%) tumors without microsatellite instability, LOH was observed for at least one 3p marker. Analysis of 27 ovarian tumors demonstrating both loss and retention of 3p markers enabled us to define four nonoverlapping minimal deletion regions (OCLOHRs): (a) OCLOHR-1 mapped distal to D3S3591 at 3p25–26; (b) OCLOHR-2 mapped between D3S1317 and D3S1259 at 3p24–25; (c) OCLOHR-3 mapped between D3S1300 and D3S1284, an area that includes the FHIT locus at 3p14.2; and (d) OCLOHR-4 mapped between D3S1284 and D3S1274 at 3p12–13, a region known to contain overlapping homozygous deletions in lung and breast tumor cell lines. However, microsatellite markers from the chromosome 3p21.3 interval homozygously deleted in lung cancer cell lines did not identify a distinct OCLOHR. The frequency and extent of 3p LOH correlated with tumor stage such that LOH at two or more OCLOHRs was present in 53% (16 of 30) of stage III tumors but only 26% (5 of 19) of stage I/II tumors (P = 0.08).

To determine the relationship between the OCLOHRs and the three candidate ovarian cancer suppression regions (OCSRs) identified previously by monochromosome transfer studies, we performed detailed genetic and physical mapping studies to define the extent of the three candidate OCSRs and to establish YAC contigs covering each region. OCSR-A at 3p25–26 and OCSR-B at 3p24 were shown to overlap with OCLOHR-1 and OCLOHR-2, respectively, providing further evidence for OCTSGs in these regions. We also show that OCSR-C overlaps with a locus at 3p21.3 previously implicated in lung and breast cancer.

This article has been cited by other articles:

				P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF]

				A. Agathanggelou, I. Bieche, J. Ahmed-Choudhury, B. Nicke, R. Dammann, S. Baksh, B. Gao, J. D. Minna, J. Downward, E. R. Maher, et al. Identification of Novel Gene Expression Targets for the Ras Association Domain Family 1 (RASSF1A) Tumor Suppressor Gene in Non-Small Cell Lung Cancer and Neuroblastoma Cancer Res., September 1, 2003; 63(17): 5344 - 5351. [Abstract] [Full Text] [PDF]

				M. Hoglund, D. Gisselsson, G. B. Hansen, T. Sall, and F. Mitelman Ovarian Carcinoma Develops through Multiple Modes of Chromosomal Evolution Cancer Res., June 15, 2003; 63(12): 3378 - 3385. [Abstract] [Full Text] [PDF]

				C. Tse, R. H. Xiang, T. Bracht, and S. L. Naylor Human Semaphorin 3B (SEMA3B) Located at Chromosome 3p21.3 Suppresses Tumor Formation in an Adenocarcinoma Cell Line Cancer Res., January 1, 2002; 62(2): 542 - 546. [Abstract] [Full Text] [PDF]

				E. N. Manderson, A.-M. Mes-Masson, J. Novak, P. D. Lee, D. Provencher, T. J. Hudson, and P. N. Tonin Expression Profiles of 290 ESTs Mapped to Chromosome 3 in Human Epithelial Ovarian Cancer Cell Lines Using DNA Expression Oligonucleotide Microarrays Genome Res., January 1, 2002; 12(1): 112 - 121. [Abstract] [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				A Martinez, R A Walker, J A Shaw, S J Dearing, E R Maher, and F Latif Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features Mol. Pathol., October 1, 2001; 54(5): 300 - 306. [Abstract] [Full Text] [PDF]

				J. Zhu and X. Chen MCG10, a Novel p53 Target Gene That Encodes a KH Domain RNA-Binding Protein, Is Capable of Inducing Apoptosis and Cell Cycle Arrest in G2-M Mol. Cell. Biol., August 1, 2000; 20(15): 5602 - 5618. [Abstract] [Full Text]

				M. D. Vos, C. A. Ellis, A. Bell, M. J. Birrer, and G. J. Clark Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis J. Biol. Chem., November 10, 2000; 275(46): 35669 - 35672. [Abstract] [Full Text] [PDF]

				J. Lee, W.-H. Ho, M. Maruoka, R. T. Corpuz, D. T. Baldwin, J. S. Foster, A. D. Goddard, D. G. Yansura, R. L. Vandlen, W. I. Wood, et al. IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1 J. Biol. Chem., January 5, 2001; 276(2): 1660 - 1664. [Abstract] [Full Text] [PDF]